342,152 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 342,152 shares of the company's stock, valued at approximately $7,538,000. BNP Paribas Financial Markets owned approximately 0.17% of Cellebrite DI at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in CLBT. Axon Enterprise Inc. purchased a new stake in Cellebrite DI in the 4th quarter valued at approximately $198,270,000. FMR LLC boosted its holdings in Cellebrite DI by 89.1% in the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock valued at $233,988,000 after purchasing an additional 5,004,587 shares in the last quarter. True Wind Capital Management L.P. boosted its holdings in Cellebrite DI by 18.2% in the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after purchasing an additional 2,130,386 shares in the last quarter. Invesco Ltd. purchased a new stake in Cellebrite DI in the 4th quarter valued at approximately $32,700,000. Finally, Principal Financial Group Inc. purchased a new stake in Cellebrite DI in the 3rd quarter valued at approximately $23,402,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

Shares of CLBT traded up $0.14 during trading hours on Friday, hitting $17.41. The stock had a trading volume of 1,845,732 shares, compared to its average volume of 1,461,446. The firm has a market cap of $4.17 billion, a P/E ratio of -12.53, a P/E/G ratio of 4.27 and a beta of 1.44. The company's fifty day simple moving average is $19.02 and its 200 day simple moving average is $20.26. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The business's quarterly revenue was up 20.0% on a year-over-year basis. During the same period last year, the company posted $0.08 EPS. As a group, sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of analyst reports. Needham & Company LLC lowered their price objective on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating on the stock in a report on Wednesday. Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. decreased their price target on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, May 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.